|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Han K, Chen X, Bian N, Ma B, Yang T, Cai
C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195
suppresses osteosarcoma cell metastasis by targeting CCND1.
Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kourti M, Sidi V and Papakonstantinou E:
Osteosarcoma in an adolescent previously treated for Hodgkin's
Disease. Hippokratia. 18:962014.PubMed/NCBI
|
|
5
|
Cui SQ and Wang H: MicroRNA-144 inhibits
the proliferation, apoptosis, invasion, and migration of
osteosarcoma cell line F5M2. Tumour Biol. 36:6949–6958. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
8
|
Zhao D, Jia P, Wang W and Zhang G:
VEGF-mediated suppression of cell proliferation and invasion by
miR-410 in osteosarcoma. Mol Cell Biochem. 400:87–95. 2015.
View Article : Google Scholar
|
|
9
|
Zhang L, Lyer AK, Yang X, Kobayashi E, Guo
Y, Mankin H, Hornicek FJ, Amiji MM and Duan Z: Polymeric
nanoparticle-based delivery of microRNA-199a-3p inhibits
proliferation and growth of osteosarcoma cells. Int J Nanomedicine.
10:2913–2924. 2015.PubMed/NCBI
|
|
10
|
Fang Z, Du R, Edwards A, Flemington EK and
Zhang K: The sequence structures of human microRNA molecules and
their implications. PLoS One. 8:e542152013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Jia LS, Yuan W, Wu Z, Wang HB, Xu
T, Sun JC, Cheng KF and Shi JG: Low miR-34a and miR-192 are
associated with unfavorable prognosis in patients suffering from
osteosarcoma. Am J Transl Res. 7:111–119. 2015.PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li M, Yu M, Liu C, Zhu H, He X, Peng S and
Hua J: MiR-34c works downstream of p53 leading to dairy goat male
germline stem-cell (mGSCs) apoptosis. Cell Prolif. 46:223–231.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, You T and Jing J: MiR-125b inhibits
cell biological progression of Ewing's sarcoma by suppressing the
PI3K/Akt signalling pathway. Cell Prolif. 47:152–160. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: MicroRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
17
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J and Lu X: The emerging roles of 3′
untranslated regions in cancer. Cancer Lett. 337:22–25. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepatocellular carcinoma. Med Oncol. 31:8442014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z,
Meng D and Wang Y: Differential expression of microRNA species in
human gastric cancer versus non-tumorous tissues. J Gastroenterol
Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Zhang F, Huang W, Sheng M and Liu T:
MiR-451 inhibits cell growth and invasion by targeting CXCL16 and
is associated with prognosis of osteosarcoma patients. Tumour Biol.
36:2041–2048. 2015. View Article : Google Scholar
|
|
24
|
Ziyan W and Yang L: MicroRNA-21 regulates
the sensitivity to cisplatin in a human osteosarcoma cell line. Ir
J Med Sci. 185:85–91. 2016. View Article : Google Scholar
|
|
25
|
Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M,
Quan ZX and Chen J: MicroRNA-212 inhibits osteosarcoma cells
proliferation and invasion by down-regulation of Sox4. Cell Physiol
Biochem. 34:2180–2188. 2014. View Article : Google Scholar
|
|
26
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar :
|
|
27
|
Bailey-Wilson JE, Amos CI, Pinney SM,
Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M,
Franklin W, et al: A major lung cancer susceptibility locus maps to
chromosome 6q23-25. Am J Hum Genet. 75:460–474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tseng RC, Chang JW, Hsien FJ, Chang YH,
Hsiao CF, Chen JT, Chen CY, Jou YS and Wang YC: Genomewide loss of
heterozygosity and its clinical associations in non small cell lung
cancer. Int J Cancer. 117:241–247. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang
Y, Yang C and Jiang Y: MiR-497 and miR-34a retard lung cancer
growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget.
6:13149–13163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen HC, Chen GH, Chen YH, Liao WL, Liu
CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and
pathway alterations in nasopharyngeal carcinoma. Br J Cancer.
100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar
|
|
32
|
Wang L, Li B, Li L and Wang T:
MicroRNA-497 suppresses proliferation and induces apoptosis in
prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T and Zhao Y: MiR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han J, Huo M, Mu M, Liu J and Zhang J:
miR-497 suppresses proliferation of human cervical carcinoma HeLa
cells by targeting cyclin E1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
30:597–600. 2014.In Chinese. PubMed/NCBI
|
|
36
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang W, Ren F, Wu Q, Jiang D, Li H, Peng
Z, Wang J and Shi H: MicroRNA-497 inhibition of ovarian cancer cell
migration and invasion through targeting of SMAD specific E3
ubiquitin protein ligase 1. Biochem Biophys Res Commun.
449:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
39
|
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang
Y and Fang L: MiRNA-497 regulates cell growth and invasion by
targeting cyclin E1 in breast cancer. Cancer Cell Int. 13:952013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen C, Zhao Z, Liu Y and Mu D:
microRNA-99a is downregulated and promotes proliferation, migration
and invasion in non-small cell lung cancer A549 and H1299 cells.
Oncol Lett. 9:1128–1134. 2015.PubMed/NCBI
|
|
42
|
Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu
W, Shu Y and Liu P: MiR-503 regulates cisplatin resistance of human
gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J
(Engl). 127:2357–2362. 2014.
|
|
43
|
Hu Q, Gong JP, Li J, Zhong SL, Chen WX,
Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation
of miRNA-452 is associated with adriamycin-resistance in breast
cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo T, Feng Y, Liu Q, Yang X, Jiang T,
Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and
modulates glioma cell functions by targeting IGF-1R. Tumour Biol.
35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Su J, Liang H, Yao W, Wang N, Zhang S, Yan
X, Feng H, Pang W, Wang Y, Wang X, et al: MiR-143 and MiR-145
regulate IGF1R to suppress cell proliferation in colorectal cancer.
PLoS One. 9:e1144202014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ullrich A, Gray A, Tam AW, Yang-Feng T,
Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et
al: Insulin-like growth factor I receptor primary structure:
Comparison with insulin receptor suggests structural determinants
that define functional specificity. EMBO J. 5:2503–2512.
1986.PubMed/NCBI
|
|
47
|
Werner H and LeRoith D: The role of the
insulin-like growth factor system in human cancer. Adv Cancer Res.
68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
49
|
Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX,
Miao DS and De W: Lentivirus-mediated RNAi knockdown of
insulin-like growth factor-1 receptor inhibits growth, reduces
invasion and enhances radiosensitivity in human osteosarcoma cells.
Mol Cell Biochem. 327:257–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang YH, Han XD, Qiu Y, Xiong J, Yu Y,
Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased
expression of insulin-like growth factor-1 receptor is correlated
with tumor metastasis and prognosis in patients with osteosarcoma.
J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar
|
